Short Bowel Syndrome Market: Current Analysis and Forecast (2021-2027)

The short bowel syndrome market is expected to register a CAGR of around 27% over the period of 2021-2027. Short bowel syndrome (SBS) is a metabolic disorder caused by dysfunction or elimination of the small intestine due to surgery for gastrointestinal disorders. The side effects of this syndrome include malabsorption, diarrhea, steatorrhea, water and electrolyte imbalances, and malnutrition. Initial treatment for short bowel syndrome includes maintaining good nutrition, maximizing the absorption area of the remaining intestine, and avoiding complications. The growing number of cases of short bowel syndrome is mainly due to an increase in diseases related to the intestine, genetic inheritance of SBS, etc. For instance, according to the National Institute of Diabetes and Digestive & Kidney Diseases, every year, short bowel syndrome affects nearly 3 out of every million people. Furthermore, the short bowel syndrome market is also anticipated to grow on account of the growing healthcare expenditure, rapid improvements in the field of healthcare have increased awareness regarding this disease, and state government with nonprofit organizations provide special incentives to market players as it promotes research & development related to short bowel syndrome.

Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc., and Nestle are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

"Amongst Product, the Glucagon-like peptide-2 (GLP2) category accounted for the majority share in the market in 2020"

Based on product, the market is classified into glucagon-like peptide- 2 (GLP2), growth hormone, glutamine, and others. Amongst products, the GLP2 category accounted for a significant share of the market. The only GLP-2 analog available on the market for the treatment of short bowel syndrome is Gattex and Revestive. the increase in prescriptions for Gattex therapy contributes to the growth of the market.

"Among Distribution Channel, the Hospital Pharmacies is expected to witness highest CAGR during the forecast period"

Based on distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and online sales. Among these, the hospital pharmacies are expected to witness a considerable CAGR during the forecast period due to an increase in patients in hospital settings and rising implementation of therapy. Moreover, patient preference for affordable and more expensive parenteral nutrition along with prescription drugs contributes to a large share of this segment.

"North America to witness significant growth during the forecast period"

For a better understanding of the market dynamics of the short bowel syndrome market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the short bowel syndrome in 2020 owing to due to the revenue generated by Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at one glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional level analysis of the industry.

Customization Options:

Global short bowel syndrome market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.